MA27582A1 - Derives benzazepine pour le traitement de troubles neurologiques - Google Patents

Derives benzazepine pour le traitement de troubles neurologiques

Info

Publication number
MA27582A1
MA27582A1 MA28405A MA28405A MA27582A1 MA 27582 A1 MA27582 A1 MA 27582A1 MA 28405 A MA28405 A MA 28405A MA 28405 A MA28405 A MA 28405A MA 27582 A1 MA27582 A1 MA 27582A1
Authority
MA
Morocco
Prior art keywords
treatment
benzazepine derivatives
neurological disorders
relates
neurological
Prior art date
Application number
MA28405A
Other languages
English (en)
Inventor
James Bamford Mark
Kenneth Dean David
Singh Sehmi Sanjeet
Matthew Wilson David
Witherington Jason
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0229820A external-priority patent/GB0229820D0/en
Priority claimed from GB0312607A external-priority patent/GB0312607D0/en
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of MA27582A1 publication Critical patent/MA27582A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La présente invention concerne des dérivés benzazépine pharmacologiquement actifs représentés par la formule générale (I) dans laquelle R1 est C3-C7 cycloalkyle éventuellement substitué par C1-C3 alkyle. L'invention concerne également des procédés permettant leur élaboration, des compositions les contenant, et leur utilisation pour le traitement de troubles neurologiques et psychiatriques.
MA28405A 2002-12-20 2005-07-20 Derives benzazepine pour le traitement de troubles neurologiques MA27582A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0229820A GB0229820D0 (en) 2002-12-20 2002-12-20 Novel compounds
GB0312607A GB0312607D0 (en) 2003-06-02 2003-06-02 Novel compounds

Publications (1)

Publication Number Publication Date
MA27582A1 true MA27582A1 (fr) 2005-10-03

Family

ID=32683982

Family Applications (1)

Application Number Title Priority Date Filing Date
MA28405A MA27582A1 (fr) 2002-12-20 2005-07-20 Derives benzazepine pour le traitement de troubles neurologiques

Country Status (28)

Country Link
US (4) US7696193B2 (fr)
EP (3) EP2186516B1 (fr)
JP (2) JP4584831B2 (fr)
KR (2) KR100765027B1 (fr)
AR (1) AR042542A1 (fr)
AT (1) ATE441417T1 (fr)
AU (1) AU2003294909B2 (fr)
BR (1) BR0317483A (fr)
CA (1) CA2509413C (fr)
CY (1) CY1109558T1 (fr)
DE (1) DE60329123D1 (fr)
DK (1) DK1572215T3 (fr)
EG (1) EG25204A (fr)
ES (3) ES2333008T3 (fr)
HK (1) HK1085647A1 (fr)
IL (2) IL169091A (fr)
IS (1) IS2907B (fr)
MA (1) MA27582A1 (fr)
MX (1) MXPA05006567A (fr)
MY (1) MY138478A (fr)
NO (2) NO331068B1 (fr)
NZ (1) NZ540148A (fr)
PL (2) PL397229A1 (fr)
PT (1) PT1572215E (fr)
RU (2) RU2423353C1 (fr)
SI (1) SI1572215T1 (fr)
TW (1) TWI323256B (fr)
WO (1) WO2004056369A1 (fr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05006567A (es) * 2002-12-20 2005-08-16 Glaxo Group Ltd Derivados de benzazepina para el tratamiento de trastornos neurologicos.
DE602004017206D1 (de) * 2003-10-23 2008-11-27 Hoffmann La Roche Benzazepin-derivate als mao-b-hemmer
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
GB0405628D0 (en) * 2004-03-12 2004-04-21 Glaxo Group Ltd Novel compounds
GB0408083D0 (en) * 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
EP1756094A1 (fr) * 2004-06-18 2007-02-28 Glaxo Group Limited 3-cycloalkylbenzazepines utilisees en tant qu'antagonistes de h3 l'histamine
GB0418267D0 (en) * 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds
US7560453B2 (en) 2005-01-07 2009-07-14 Glaxo Group Limited 6-(2, 3, 4, 5-tetrahydro-1H-benzo [D] azepin-7-yloxy) -nicotamide derivatives as radio labelled ligands
GB0513886D0 (en) 2005-07-06 2005-08-10 Glaxo Group Ltd Novel compounds
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
WO2007045989A1 (fr) * 2005-10-20 2007-04-26 Pfizer Limited Dérivés de pyridyle pouvant être employés en tant que ligands h3
US7943605B2 (en) 2005-10-27 2011-05-17 Ucb Pharma S.A. Compounds comprising a lactam or a lactam derivative moiety, processes for making them, and their uses
WO2007057329A1 (fr) * 2005-11-18 2007-05-24 F. Hoffmann-La Roche Ag Derives d’azaindole-2-carboxamide
CA2653940C (fr) * 2006-05-30 2015-07-14 Janssen Pharmaceutica N.V. Composes de pyridyl amide substitues utilises comme modulateurs du recepteur de l'histamine h3
WO2007149728A2 (fr) * 2006-06-20 2007-12-27 Alcon Research, Ltd. Dérivés d'aryl et d'hétéroaryl tétrahydrobenzazépine et leur utilisation pour traiter le glaucome
US9108948B2 (en) * 2006-06-23 2015-08-18 Abbvie Inc. Cyclopropyl amine derivatives
CN103382174A (zh) 2006-06-23 2013-11-06 雅培制药有限公司 作为组胺h3受体调节物的环丙胺衍生物
GB2441014A (en) * 2006-09-14 2008-02-20 Glaxo Group Ltd Polymorphic form of 6-(3-cyclobuty1-2,3,4,5-tetrahydro-1H-benzo[d]azepin-7-yloxy)-N-methyl-nicotinamide hydrochloride for use in therapy
CL2008000596A1 (es) * 2007-03-01 2008-09-05 Glaxo Group Ltd Forma de dosificacion que comprende 1-(6-[(3-ciclobutil-2,3,4,5-tetrahidro-1h-3-benzazepin-7-il)oxi]-3-piridinil)-2-pirrolidinona, un estabilizador, un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
CL2008000597A1 (es) * 2007-03-01 2008-09-05 Glaxo Group Ltd Forma de dosificacion que comprende 6-(3-ciclobutil-2,3,4,5-tetrahidro-1h-benzo[d]azepin-7-il oxi)-n-metil nicotinamida, un estabilizante y un excipiente; procedimiento de preparacion; y su uso para tratar enfermedades neurologicas.
CN102558001B (zh) 2007-05-22 2015-09-23 惠氏有限责任公司 制造酰肼的改良方法
PE20091199A1 (es) * 2007-09-06 2009-09-12 Glaxo Group Ltd Derivado de piperazina que tiene afinidad por el receptor de histamina h3
US8383657B2 (en) 2007-12-21 2013-02-26 Abbott Laboratories Thiazolylidine urea and amide derivatives and methods of use thereof
WO2010094643A1 (fr) 2009-02-17 2010-08-26 Glaxo Group Limited Dérivés de quinoline et applications associées dans la rhinite et l'urticaire
US9186353B2 (en) * 2009-04-27 2015-11-17 Abbvie Inc. Treatment of osteoarthritis pain
WO2011051423A1 (fr) 2009-11-02 2011-05-05 Glaxo Group Limited Traitement ou prophylaxie de la démence, des troubles neurodégénératifs, de la schizophrénie, de l'adhd de la somnolence ou de l'épilepsie
WO2011083316A1 (fr) * 2010-01-08 2011-07-14 Takeda Pharmaceutical Company Limited Dérivés de la benzazépine destinés à traiter des troubles du système nerveux central
WO2012037258A1 (fr) 2010-09-16 2012-03-22 Abbott Laboratories Procédés de préparation de dérivés cyclopropyliques substitués en 1,2
DK2694492T3 (en) * 2011-02-23 2015-11-09 Suven Life Sciences Ltd NOVEL COMPOUNDS AS HISTAMINE H3 receptor ligands
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
CN103415513B (zh) 2011-03-14 2016-01-20 勃林格殷格翰国际有限公司 白三烯产物的苯并二氧杂环己烷抑制剂
EP2734516B1 (fr) 2011-07-19 2015-06-17 Boehringer Ingelheim International GmbH Éthers d'arylpyrazole en tant qu'inhibiteurs de leucotriène a4 hydrolase
RU2014133544A (ru) * 2012-01-16 2016-03-20 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Терапевтические применения
CN104114538B (zh) * 2012-01-16 2016-04-13 葛兰素史克知识产权发展有限公司 治疗用途
US9662339B2 (en) 2012-03-06 2017-05-30 Boehringer Ingelheim International Gmbh Benzodioxane inhibitors of leukotriene production for combination therapy
WO2013151982A1 (fr) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Méthodes et composés utiles pour traiter le prurit, et procédés d'identification desdits composés
EP2647377A1 (fr) 2012-04-06 2013-10-09 Sanofi Utilisation d'un antagoniste du récepteur h3 pour le traitement de la maladie d'Alzheimer
JP6256467B2 (ja) * 2012-07-17 2018-01-10 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成を阻害するピラゾール誘導体
JP2016523982A (ja) 2013-07-15 2016-08-12 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ロイコトリエン生成の阻害剤
EP3022193B1 (fr) 2013-07-15 2017-04-26 Boehringer Ingelheim International GmbH Inhibiteurs de production de leucotriènes
WO2016123629A1 (fr) * 2015-01-30 2016-08-04 Vanderbilt University Composés à substituants indazole et azaindazole en tant que potentiateurs allostériques de mglur4, compositions, et méthodes de traitement de dysfonctionnements neurologiques
EP4251148A1 (fr) 2020-11-27 2023-10-04 Richter Gedeon Nyrt. Antagonistes/agonistes inverses du récepteur h3 de l'histamine pour le traitement d'un trouble du spectre autistique
EP4426284A1 (fr) 2021-11-01 2024-09-11 Alkahest, Inc. Modulateurs de benzodioxane de leucotriène a4 hydrolase (lta4h) pour la prévention et le traitement de maladies liées au vieillissement

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3393192A (en) * 1965-04-26 1968-07-16 Schering Corp Novel benzazepines
US4233217A (en) * 1968-03-11 1980-11-11 Pennwalt Corporation Substituted 1,2,4,5-tetrahydro-3H, 3 benzazepines
CA974989A (en) 1968-03-11 1975-09-23 Wallace And Tiernan Inc. Process for preparing 1,2,4,5-tetrahydro-3h,3-benzazepines and products obtained thereby
DE2207430C3 (de) 1972-02-14 1982-05-13 Pennwalt Corp., 19102 Philadelphia, Pa. 1,2,4,5-Tetrahydro-3H-3-benzazepin, ein Verfahren zu ihrer Herstellung und diese enthaltendes pharmazeutisches Mittel
US4210749A (en) * 1974-11-12 1980-07-01 Pennwalt Corporation Substituted 1,2,4,5-tetrahydro-3H,3 benzazepines
US4206210A (en) * 1977-01-19 1980-06-03 Smithkline Corporation Alkylthio-7,8-dihdroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepines having dopaminergic activity
US4843081A (en) * 1984-09-04 1989-06-27 Rorer Pharmaceutical Corporation Aryl and heteroaryl substituted cycloalkyl compounds
US5175157A (en) * 1985-11-27 1992-12-29 Boehringer Ingelheim Gmbh Cyclic amine derivatives, pharmaceutical compositions containing these compounds and methods for preparing them
DE3717561A1 (de) 1987-05-25 1988-12-08 Thomae Gmbh Dr K Indol-, isochinolin- und benzazepinderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
JPS6394239A (ja) 1986-10-08 1988-04-25 Konica Corp 色素画像の安定性を改良したハロゲン化銀写真感光材料
ZA882080B (en) * 1987-03-27 1989-04-26 Schering Corp Substituted benzazepines,their preparation and pharmaceutical compositions containing them
DK325188D0 (da) 1988-06-15 1988-06-15 Novo Industri As Hidtil ukendte benzazepinderivater
FR2642756B1 (fr) 1989-02-07 1994-03-04 Sanofi Derives cycloaminoalkoxyphenyle, leur procede de preparation ainsi que les compositions pharmaceutiques ou veterinaires en contenant
US4959374A (en) * 1989-07-06 1990-09-25 Beecham Group P.L.C. Novel compounds
IL98487A0 (en) 1990-06-15 1992-07-15 Schering Corp 8-lower alkyl-5-cycloalkyl or 5-cycloalkenyl substituted benzazepines and pharmaceutical compositions containing them
TW197435B (fr) 1990-11-22 1993-01-01 Takeda Pharm Industry Co Ltd
AU1927992A (en) 1991-06-21 1993-01-25 Smithkline Beecham Plc Medicaments
GB9116824D0 (en) 1991-08-05 1991-09-18 Smithkline Beecham Corp Chemical compounds
GB9119467D0 (en) 1991-09-12 1991-10-23 Smithkline Beecham Corp Chemical compounds
JPH05194406A (ja) 1991-11-12 1993-08-03 Yoshitomi Pharmaceut Ind Ltd 新規アミド化合物
US5241065A (en) 1992-02-25 1993-08-31 Schering Corporation 2,3,4,5-tetrahydro-1h-3-benzazepines having anti-psychotic activity
JPH05239024A (ja) 1992-02-28 1993-09-17 Takeda Chem Ind Ltd 縮合複素環カルボン酸誘導体、その製造法、中間体および剤
JPH07509694A (ja) 1992-05-14 1995-10-26 ベイラー・カレッジ・オブ・メディシン 突然変異したステロイドホルモン受容体，その使用方法および遺伝子治療のための分子スイッチ
US5364791A (en) * 1992-05-14 1994-11-15 Elisabetta Vegeto Progesterone receptor having C. terminal hormone binding domain truncations
DE4332168A1 (de) 1993-02-22 1995-03-23 Thomae Gmbh Dr K Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
SE9300657D0 (sv) 1993-02-26 1993-02-26 Astra Ab New compounds
US5387685A (en) 1993-07-16 1995-02-07 American Cyanamid Co MDR reversal agents
WO1995013075A1 (fr) 1993-11-12 1995-05-18 Cell Therapeutics, Inc. Procede pour eviter les lesions des tissus provoquees par l'hypoxemie
DK0730601T3 (da) 1993-11-18 2005-06-06 Univ Washington Forbindelser og farmaceutiske præparater til behandling af profylakse af bakterieinfektioner
DE4429079A1 (de) 1994-08-17 1996-02-22 Thomae Gmbh Dr K Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE19530996A1 (de) 1995-08-23 1997-02-27 Boehringer Mannheim Gmbh Cyclische Guanidine, Verfahren zu ihrer Herstellung und Arzneimittel
EP0920417A4 (fr) 1996-08-15 1999-12-29 Smithkline Beecham Corp Antagonistes du recepteur de l'il-8
US5932590A (en) 1996-12-05 1999-08-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
EP0952826B1 (fr) 1997-01-17 2001-11-14 Takeda Chemical Industries, Ltd. Agent combine contenant de l'idebenone pour le traitement de la maladie d'alzheimer
GB9724372D0 (en) 1997-11-18 1998-01-14 Smithkline Beecham Plc Novel compounds
US6348478B1 (en) 1997-11-20 2002-02-19 Teijin Limited Biphenylamidine derivatives
CN1158277C (zh) 1998-02-02 2004-07-21 Lg化学株式会社 具有哌啶结构的法尼转移酶抑制剂及其制备方法
EP0937723A1 (fr) 1998-02-18 1999-08-25 Roche Diagnostics GmbH Nouveaux sulfonamides, procédé pour leur préparation et médicaments les contenant
ID26403A (id) 1998-04-20 2000-12-21 Basf Ag Amida baru yang tersubstitusi, pembuatan dan penggunaannya
HUP0103093A3 (en) 1998-04-29 2002-03-28 Smithkline Beecham Plc Quinolones used as mrs inhibitors and bactericides and process for their preparation
EP0982300A3 (fr) * 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines comme antagonistes du recepteur histamine H3 et leur application thérapeutique
GB9816982D0 (en) 1998-08-05 1998-09-30 Smithkline Beecham Plc Novel compounds
HUP0104280A3 (en) 1998-10-08 2002-07-29 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors, process for their preparation, medicaments containing them
CA2347095A1 (fr) 1998-10-16 2000-04-27 Takeda Chemical Industries, Ltd. Composes azotes hererocycliques condenses; procede de fabrication et agents les renfermant
EP1313426A2 (fr) 1998-12-24 2003-05-28 Bristol-Myers Squibb Pharma Company Benzodiazepines succinoylamino utilisees comme inhibiteurs de la production de proteine a-beta
GB9914255D0 (en) 1999-06-18 1999-08-18 Lilly Forschung Gmbh Pharmaceutical compounds
CA2375628A1 (fr) 1999-07-09 2001-01-18 Isis Innovation Limited Composes destines a l'inhibition de maladies et a la preparation de cellules a transplanter
DE60006618T2 (de) * 1999-08-06 2004-09-23 F. Hoffmann-La Roche Ag Tetrahydro-benzo(d)azepine und deren Verwendung als metabotrope Glutamatrezeptor-Antagonisten
AU1569501A (en) 1999-11-09 2001-06-06 Eli Lilly And Company Beta-aminoacid compounds useful for inhibiting beta-amyloid peptide release and/or its synthesis
US6809092B2 (en) 2000-01-26 2004-10-26 Ono Pharmaceutical Co., Ltd. Benezene-fused heteroring derivatives and pharmaceutical agents comprising the same as active ingredient
JP2001226269A (ja) 2000-02-18 2001-08-21 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
DE60115132T2 (de) 2000-04-21 2006-07-06 Pfizer Products Inc., Groton Thyroid-Rezeptorliganden
ATE310728T1 (de) 2000-05-11 2005-12-15 Bristol Myers Squibb Co Tetrahydroisochinolin-analoga als wachstumshormon-sekretagoga
JP2002371059A (ja) * 2000-05-16 2002-12-26 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
WO2001087834A1 (fr) * 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
WO2002002530A1 (fr) 2000-07-04 2002-01-10 Takeda Chemical Industries, Ltd. Antagoniste de gpr14
EP1308513A4 (fr) 2000-08-10 2008-07-09 Takeda Pharmaceutical Utilisation de polypeptide
US20030207863A1 (en) * 2000-08-25 2003-11-06 Hiroaki Fukumoto Preventives and remedies for central nervous system diseases
IL155873A0 (en) 2000-11-14 2003-12-23 Smithkline Beecham Plc Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
UA77165C2 (en) 2000-11-17 2006-11-15 Lilly Co Eli (n)-((s)-2-hydroxy-3-methyl-butyryl)-1-(l-alaninyl)-(s)-1-amino-3-methyl-4,5,6,7-tetrahydro-2h-3-benzazepin-2-one dihydrate, processes for manufacturing and pharmaceutical composition
FR2819512B1 (fr) 2001-01-18 2003-02-21 Servier Lab Nouveaux composes cyclo[d] azepane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
IL157029A0 (en) 2001-02-02 2004-02-08 Bristol Myers Squibb Co Azaindoleoxoacetic piperazine derivatives and pharmaceutical compositions containing the same
AU2002357692A1 (en) 2001-11-09 2003-05-26 Bristol-Myers Squibb Company Tetrahydroisoquinoline analogs as modulators of chemokine receptor activity
US7196108B2 (en) 2002-03-08 2007-03-27 Incyte San Diego Inc. Bicyclic heterocycles for the treatment of diabetes and other diseases
US6953787B2 (en) 2002-04-12 2005-10-11 Arena Pharmaceuticals, Inc. 5HT2C receptor modulators
WO2003090751A1 (fr) 2002-04-26 2003-11-06 Pfizer Products Inc. Inhibiteurs de metalloproteinase a base de pyrimidine-2, 4, 6-trione
EP1501833B1 (fr) 2002-04-26 2005-11-02 Pfizer Products Inc. Inhibiteurs de la metalloproteinase n-substitues-heteroaryloxy-aryl-spiro-pyrimidine-2,4,6-trione
JP2006500376A (ja) * 2002-08-20 2006-01-05 イーライ・リリー・アンド・カンパニー ヒスタミンｈ３受容体アンタゴニストとしての置換アゼピン、製造および治療上の使用
US7381719B2 (en) * 2002-09-19 2008-06-03 Eli Lilly And Company Diaryl ethers as opioid receptor antagonist
GB0224083D0 (en) 2002-10-16 2002-11-27 Glaxo Group Ltd Novel compounds
GB0224557D0 (en) 2002-10-22 2002-11-27 Glaxo Group Ltd Novel compounds
MXPA05006567A (es) * 2002-12-20 2005-08-16 Glaxo Group Ltd Derivados de benzazepina para el tratamiento de trastornos neurologicos.
AU2003292625B2 (en) * 2002-12-26 2008-07-24 Eisai R & D Management Co., Ltd. Selective estrogen receptor modulators
JP2006516989A (ja) 2003-02-07 2006-07-13 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー 抗菌剤として使用するための二環式環によりｎ−置換されたオキサゾリジノン誘導体
CA2536659A1 (fr) 2003-08-08 2005-02-17 Glaxo Group Limited Procede
DE602004017206D1 (de) 2003-10-23 2008-11-27 Hoffmann La Roche Benzazepin-derivate als mao-b-hemmer
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
US8207160B2 (en) 2003-12-18 2012-06-26 Abbott Gmbh & Co. Kg Tetrahydrobenzazepines and their use in he modulation of the dopamine D3 receptor
GB0405628D0 (en) * 2004-03-12 2004-04-21 Glaxo Group Ltd Novel compounds
GB0408083D0 (en) * 2004-04-08 2004-05-12 Glaxo Group Ltd Novel compounds
EP1756094A1 (fr) * 2004-06-18 2007-02-28 Glaxo Group Limited 3-cycloalkylbenzazepines utilisees en tant qu'antagonistes de h3 l'histamine
GB0418267D0 (en) * 2004-08-16 2004-09-15 Glaxo Group Ltd Novel compounds

Also Published As

Publication number Publication date
CY1109558T1 (el) 2014-08-13
US8207331B2 (en) 2012-06-26
EG25204A (en) 2011-11-14
US7799773B2 (en) 2010-09-21
JP5315299B2 (ja) 2013-10-16
PL377315A1 (pl) 2006-01-23
AR042542A1 (es) 2005-06-22
EP2186516B1 (fr) 2013-01-16
RU2423353C1 (ru) 2011-07-10
NO332218B1 (no) 2012-07-30
AU2003294909A1 (en) 2004-07-14
NO20053384L (no) 2005-09-15
BR0317483A (pt) 2005-11-16
SI1572215T1 (sl) 2010-01-29
IL202827A (en) 2011-08-31
US20060040918A1 (en) 2006-02-23
RU2009138602A (ru) 2011-04-27
MXPA05006567A (es) 2005-08-16
DE60329123D1 (de) 2009-10-15
JP4584831B2 (ja) 2010-11-24
KR100897642B1 (ko) 2009-05-14
KR20050088195A (ko) 2005-09-02
EP2186516A1 (fr) 2010-05-19
PL397229A1 (pl) 2012-02-27
PL220722B1 (pl) 2015-12-31
JP2006512412A (ja) 2006-04-13
NO20053384D0 (no) 2005-07-12
ATE441417T1 (de) 2009-09-15
ES2401216T3 (es) 2013-04-17
US20070299056A1 (en) 2007-12-27
ES2333008T3 (es) 2010-02-16
MY138478A (en) 2009-06-30
NO331068B1 (no) 2011-09-26
NO20110408L (no) 2005-09-15
KR20070089762A (ko) 2007-08-31
TW200500344A (en) 2005-01-01
CA2509413C (fr) 2012-05-01
EP2133340B1 (fr) 2013-01-16
EP1572215A1 (fr) 2005-09-14
RU2388752C2 (ru) 2010-05-10
WO2004056369A1 (fr) 2004-07-08
HK1085647A1 (en) 2006-09-01
IL169091A0 (en) 2007-07-04
CA2509413A1 (fr) 2004-07-08
AU2003294909B2 (en) 2007-05-17
US7704994B2 (en) 2010-04-27
IS2907B (is) 2014-11-15
US7696193B2 (en) 2010-04-13
ES2401319T3 (es) 2013-04-18
IS7941A (is) 2005-07-18
DK1572215T3 (da) 2010-01-11
JP2010248239A (ja) 2010-11-04
US20100145040A1 (en) 2010-06-10
KR100765027B1 (ko) 2007-10-09
PT1572215E (pt) 2009-12-09
EP2133340A1 (fr) 2009-12-16
IL169091A (en) 2011-11-30
NZ540148A (en) 2007-11-30
EP1572215B1 (fr) 2009-09-02
US20090105226A1 (en) 2009-04-23
TWI323256B (en) 2010-04-11
RU2005122932A (ru) 2006-04-10

Similar Documents

Publication Publication Date Title
MA27582A1 (fr) Derives benzazepine pour le traitement de troubles neurologiques
MA27675A1 (fr) Derives de piperazine et leur utilisation dans le traitement de maladies neurologiques et psychiatriques
MA27568A1 (fr) Derives de pyrrolopyrimidine
MA30355B1 (fr) Derives d'azabicyclo [3. 1. 0] hexyle utilises comme modulateurs des recepteurs de la dopamine d3
MA31894B1 (fr) Composes organiques
CA2383779A1 (fr) Derives de n-(indolcarbonyl-)piperazine
AP1860A (en) Aryl fused azapolycyclic compounds.
TNSN05250A1 (fr) Pyrimidinones substituees
CA2536870A1 (fr) Composes de phenyle ou de pyridyle amide utiles comme antagonistes de la prostaglandine e2
TNSN07167A1 (fr) Indoles substitues, compositions les contenant, procede de fabrication et utilisation
JP2013177421A (ja) Ｐｄｅ４の二環式ヘテロアリール阻害剤
AR047076A1 (es) Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas
FI20000085A (fi) Menetelmä terapeuttisesti aktiivisten 4-amino-substituoitujen 2-azabicyklo/3.3.1/nonaanijohdannaisten valmistamiseksi
MXPA05010824A (es) Compuestos biciclicos como antagonistas del receptor nr2b.
IL176546A0 (en) Imidazoline derivatives having cb1-antagonistic activity
TW200502221A (en) Novel lactams and uses thereof
MA28286A1 (fr) Dérivés de 1-N-phenyl-amino-1H-imidazole et compositions pharmaceutiques les contenant
AU8811401A (en) Spiro compounds and adhesion molecule inhibitors containing the same as the active ingredient
BG103842A (en) 5,7-disubstituted 4-aminopyrido [2,3-d]pyrimidine compounds and their application as adenosinekinase inhibitors
MA27905A1 (fr) Pyrazolines utilisees comme antagonistes par-1 pour traiter des maladies cardio-vasculaires
EP0780125A3 (fr) Composition pharmaceutique contenant un dérivé de l'hydantoine et son utilisation
TNSN08138A1 (fr) Derives d'imidazole pour le traitement de troubles neurologiques
TR200002808T2 (tr) İlaç olarak yararlı C11 oksimil ve hidroksilamino prostaglandinleri
MA26734A1 (fr) Derives de 1-trifluoromethyl -4-hydroxy- 7-piperidinyl- aminomethylchromane, procede pour leur preparation et compositions pharmaceutiques les contenant
DE69925160D1 (de) Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität